| Literature DB >> 27042260 |
Aburrahman Gun1, Mehmet Kaya Ozer2, Sedat Bilgic3, Nevin Kocaman4, Gonca Ozan5.
Abstract
Fructose corn syrup is cheap sweetener and prolongs the shelf life of products, but fructose intake causes hyperinsulinemia, hypertriglyceridemia, and hypertension. All of them are referred to as metabolic syndrome and they are risk factors for cardiovascular diseases. Hence, the harmful effects of increased fructose intake on health and their prevention should take greater consideration. Caffeic Acid Phenethyl Ester (CAPE) has beneficial effects on metabolic syndrome and vascular function which is important in the prevention of cardiovascular disease. However, there are no known studies about the effect of CAPE on fructose-induced vascular dysfunction. In this study, we examined the effect of CAPE on vascular dysfunction due to high fructose corn syrup (HFCS). HFCS (6 weeks, 30% fed with drinking water) caused vascular dysfunction, but treatment with CAPE (50 micromol/kg i.p. for the last two weeks) effectively restored this problem. Additionally, hypertension in HFCS-fed rats was also decreased in CAPE supplemented rats. CAPE supplements lowered HFCS consumption-induced raise in blood glucose, homocysteine, and cholesterol levels. The aorta tissue endothelial nitric oxide synthase (eNOS) production was decreased in rats given HFCS and in contrast CAPE supplementation efficiently increased its production. The presented results showed that HFCS-induced cardiovascular abnormalities could be prevented by CAPE treatment.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27042260 PMCID: PMC4793141 DOI: 10.1155/2016/3419479
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Levels of various biochemical parameters in blood serum of rats in this study.
| Groups | Glukoz | Cholesterol | HDL | LDL | Triglyceride | Uric acid | Homocysteine |
|---|---|---|---|---|---|---|---|
| Control | 133 ± 5.32 | 49.16 ± 4.91 | 15.06 ± 3.06 | 5.75 ± 0.91 | 29.33 ± 11.77 | 0.73 ± 0.60 | 16.63 ± 9.50 |
| HFCS | 151 ± 5.13 | 67.50 ± 6.25 | 18.09 ± 1.05 | 11.75 ± 2.66 | 64.50 ± 11.71 | 1.28 ± 0.17 | 55.21 ± 9.17 |
| HFCS + CAPE | 121 ± 13.94 | 59.50 ± 2.66# | 15.35 ± 1.96 | 9.1 ± 1.57 | 58.33 ± 9.41 | 1.31 ± 0.19 | 24.53 ± 8.80# |
P < 0.05, control versus HFCS.
# P < 0.05, HFCS versus HFCS + CAP.
Blood pressure values in the rats in this study.
| Groups | First day (mmHg) | Forty-second day (mmHg) |
|---|---|---|
| Control | 108.83 ± 3.37 | 110.83 ± 2.22 |
| HFCS | 108.17 ± 3.76 | 130.17 ± 8.03 |
| HFCS + CAPE | 105.33 ± 3.77 | 108.83 ± 2.31 |
P < 0.05, control versus HFCS.
# P < 0.05, HFCS versus HFCS + CAPE.
Figure 1The phenylephrine dose-response curve in the rats' thoracic aorta. ¥ P < 0.05, control versus HFCS. # P < 0.05, HFCS versus HFCS + CAPE.
Figure 2The acetylcholine dose-response curve in the rats' thoracic aorta.
Figure 3The eNOS immunoreactivity in the control group of rats' endothelium (thin arrow) and adventitia (thick arrow) of thoracic aorta, ×400.
Figure 4HFCS-fed group of rats' vascular endothelial tissues, eNOS immunoreactivity not observed, ×400.
Figure 5The eNOS immunoreactivity in the HFCS + CAPE treated rats' endothelium (thin arrow) and adventitia (thick arrow) of thoracic aorta, ×400.